Monopar Therapeutics(NASDAQ) MNPR

Monopar Therapeutics Inc. creates medicines to treat rare genetic conditions and advanced cancers. These drugs help people whose bodies cannot process copper or who have hard-to-treat tumors. The company focuses on making therapies that are easier to take and more precise than current options.

The Pipeline for Patients

• ALXN1840: An oral, once-daily drug candidate designed to remove toxic copper from the body in patients with Wilson disease.
• MNPR-101-Zr: A radiopharmaceutical imaging agent in Phase 1 trials used to identify advanced solid tumors in patients.
• MNPR-101-Lu: A therapeutic agent in Phase 1a trials that delivers radiation directly to cancer cells expressing the urokinase plasminogen activator receptor (uPAR).
• MNPR-101-Ac225: A preclinical radiotherapy that uses alpha-emitting isotopes to target and destroy aggressive cancer cells.

Strategic Steps Forward

• In-licensed the ALXN1840 program from Alexion in Oct. 2024 to lead its global development and commercialization.
• Initiated a rolling submission of a New Drug Application for ALXN1840 to the Food and Drug Administration (FDA) in July 2026.
• Received FDA Rare Pediatric Disease designation for ALXN1840 in June 2026, creating potential for a Priority Review Voucher.
• Launched a Phase 1a clinical trial for the radiotherapy MNPR-101-Lu in Oct. 2024.
• Partnered with Excel Diagnostics and Nuclear Oncology Center in June 2025 to open an Expanded Access Program for radiopharmaceutical agents.

Expertise and Precision

The company utilizes a proprietary antibody that targets uPAR, a protein found on many aggressive cancers like pancreatic and breast cancer. Management leverages prior experience in drug approvals and multi-million dollar company sales to reduce clinical development risks.

Tracking the Capital

• Cash, cash equivalents, and investments totaled $134.3 million as of June 30, 2026.
• Net loss was $5.3 million for the three-month period ended June 30, 2026, compared to $2.5 million for the same period in 2025.
• Research and development expenses rose to $8.3 million for the six-month period ended June 30, 2026, up $4.9 million year over year.
• Interest income reached $2.6 million for the six-month period ended June 30, 2026, following a capital raise in Sept. 2025.
• Management expects current funds to support operations through at least Dec. 31, 2027.

Bottom Line

Monopar has transitioned from early research to late-stage drug development and active clinical trials. Its progress with Wilson disease and radiopharmaceuticals positions the firm as a multi-program biotechnology company.